### 1 Ethnic differences in the manifestation of early-onset type 2 diabetes

- 2 Davis Kibirige<sup>1,2</sup>, Anita V. Hill<sup>3,4</sup>, Jean Claude Katte<sup>3,5</sup>, Isaac Sekitoleko<sup>1</sup>, William
- <sup>3</sup> Lumu<sup>6</sup>, Julieanne Knupp<sup>3</sup>, Steven Squires<sup>3</sup>, Andrew T Hattersley<sup>3,4</sup>, Liam Smeeth<sup>7</sup>,
- 4 Angus G. Jones<sup>3,4\*</sup>, Moffat J. Nyirenda<sup>1,7\*</sup>

#### 5 Author affiliations

- 6 1. Non-Communicable Diseases Program, Medical Research Council/Uganda
- Virus Research Institute and London School of Hygiene and Tropical Medicine
   Uganda Research Unit, Entebbe Uganda.
- 9 2. Department of Medicine, Uganda Martyrs Hospital Lubaga, Kampala Uganda.
- Department of Clinical and Biomedical Sciences, University of Exeter Medical
   School, Barrack Road, Exeter, UK.
- 4. Department of Diabetes and Endocrinology, Royal Devon University
   Healthcare NHS Foundation Trust, Exeter, UK.
- Department of Non-Communicable Diseases Research, RSD Institute,
   Yaoundé, Cameroon
- 16 6. Department of Medicine, Mengo Hospital, Kampala Uganda.
- Department of Non-Communicable Diseases Epidemiology, Faculty of
   Epidemiology and Population Health, London School of Hygiene and Tropical

#### 19 Corresponding author

- 20 Davis Kibirige
- 21 Email: <u>kibirigedavis@gmail.com</u>.
- 22 \* Joint senior authors
- 23 **Word count:** 2,277 words.

<sup>25</sup> NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 26 ABSTRACT

#### 27 Aims/Hypothesis

We undertook phenotypic characterization of early-onset and late-onset type 2 diabetes (T2D) in adult Black African and White European populations with recently diagnosed T2D to explore ethnic differences in the manifestation of early-onset T2D.

### 31 Methods

Using the Uganda Diabetes Phenotype study cohort of 500 adult Ugandans and the UK StartRight study cohort of 714 White Europeans with recently diagnosed islet autoantibody negative type 2 diabetes, we compared the phenotypic characteristics of participants with early-onset T2D (diagnosed at <40 years) and late-onset T2D (diagnosed at ≥40 years).

#### 37 **Results**

One hundred and thirty four adult Ugandans and 113 White Europeans had early-38 onset T2D. Compared with late-onset T2D, early-onset T2D in White Europeans was 39 significantly associated with a female predominance (52.2% vs. 39.1%, p=0.01), 40 increased body mass index (mean [95% CI]- 36.7 [35.2-38.1] kg/m<sup>2</sup> vs. 33.0 [32.4-41 33.6] kg/m<sup>2</sup>, p<0.001), waist circumference (112.4 [109.1-115.6] cm vs. 108.8 [107.6-42 110.1] cm, p=0.06), and a higher frequency of obesity (82.3% vs. 63.4%, p<0.001). 43 No difference was seen with the post-meal C-peptide levels as a marker of beta-cell 44 function (mean [95% CI]- 2130.94 [1905.12-2356.76] pmol/L vs. 2039.72 [1956.52-45 2122.92], p=0.62). 46

Conversely, early-onset T2D in Ugandans was associated with less adiposity (mean
[95% CI] waist circumference- 93.1 [89.9-96.3] cm vs. 97.4 [95.9-98.8] cm, p=0.006)
and a greater degree of beta-cell dysfunction (120-minute post-glucose load C-peptide
mean (95% CI) level- 896.08 [780.91-1011.24] pmol/L vs 1310.10 [1179.24-1440.95]

- 51 pmol/L, p<0.001), without female predominance (53.0% vs. 57.9%, p=0.32) and 52 differences in the body mass index (mean [95% CI]- 27.3 [26.2-28.4] kg/m<sup>2</sup> vs. 27.9
- 53 [27.3-28.5] kg/m<sup>2</sup>, p=0.29).

# 54 **Conclusions/Interpretation**

- 55 These differences in the manifestation of early-onset T2D underscore the need for
- <sup>56</sup> ethnic-specific therapeutic and preventive approaches for the condition.

# 57 Keywords

- 58 Black Africans, early-onset type 2 diabetes, ethnic differences, manifestation,
- 59 phenotypic differences, White Europeans

# 60 RESEARCH IN CONTEXT

# 61 What is already known about this subject?

- Globally, the burden of early-onset type 2 diabetes (T2D) is rapidly increasing.
- Evidence from studies conducted in Asians and White populations of European
- 64 ancestry has shown that early-onset T2D is characterized by a female
- 65 preponderance, increased obesity, rapid decline in the beta-cell function, and
- a high prevalence of diabetes-related complications.
- 67 What is the key question?
- Does early-onset type 2 diabetes manifest differently in Black Africans and
   White populations of European ancestry with recently diagnosed type 2
   diabetes?

# 71 What are the new findings?

Striking differences in the manifestation of early-onset type 2 diabetes were
 observed in adult Ugandans and White Europeans with recently diagnosed type
 2 diabetes.

Early-onset type 2 diabetes in adult White populations of European ancestry
 was characterized by female predominance and increased adiposity. In
 contrast, less adiposity, lower pancreatic beta-cell function, and absence of
 female predominance were observed in adult Ugandans with early-onset type
 2 diabetes.

80 How might this impact on clinical practice in the foreseeable future?

- Because of these phenotypic differences, the preventive and therapeutic
   strategies for early-onset type 2 diabetes should be individualized to ethnicity
   and population.
- 84

#### 85 **INTRODUCTION**

Globally, the burden of early-onset type 2 diabetes (T2D), defined as T2D diagnosed 86 at <40 years, is rapidly increasing [1, 2]. Most of this evidence has been derived from 87 Asian and White populations of European ancestry [3-8]. Data from these populations, 88 particularly in high-income countries have shown that, compared with late-onset T2D, 89 early-onset T2D is characterized by a female preponderance, increased obesity, rapid 90 decline in the beta-cell function (reflecting an aggressive phenotype), and a high 91 prevalence of diabetes-related complications [7, 9-13]. The condition is thought to 92 develop due to a close interplay between genetics and environmental factors, with 93 adiposity and genetic susceptibility as key features driving the early development of 94 this condition [9, 10]. 95

In contrast, evidence on the clinical and genetic profile of early-onset type 2 diabetes
in adult Black African populations is limited [14, 15]. We also lack rigorous studies
comparing the phenotypic characteristics of early-onset T2D (where islet-cell
autoimmunity has been excluded) in Black adult Africans and White populations of

European ancestry. To address this gap, we compared the demographic, clinical, anthropometric, and metabolic characteristics of adult Ugandans and White Europeans with early-onset T2D (diagnosed at <40 years) and late-onset T2D (diagnosed at  $\geq$ 40 years) recruited in the Uganda Diabetes Phenotype (UDIP) and the United Kingdom StartRight studies, respectively, with an overarching aim of exploring whether differences in the manifestation of early-onset T2D exist between these two distinct populations.

#### 107 METHODS

108 The participants in this study were recruited in the UDIP and StartRight studies conducted in Uganda and the United Kingdom (UK), respectively. The UDIP study 109 aimed to undertake rigorous phenotypic characterization of 568 adult Ugandans (aged 110 ≥18 years) with recently diagnosed diabetes (diabetes diagnosed in the preceding 111 three months). The study participants were recruited from February 2019 to October 112 113 2020 from the adult diabetes outpatient clinics of seven public and faith-based private not-for-profit secondary hospitals in Central and Southwestern Uganda. All pregnant 114 women with recently diagnosed diabetes were excluded from the study. 115

The StartRight study was a prospective multi-center study conducted across 55 sites 116 in the UK that aimed to provide robust clinical evidence on accurate classification of 117 diabetes at the time of diagnosis and early identification of patients who will rapidly 118 require insulin treatment (<u>https://www.clinicaltrials.gov/study/NCT02287506</u>). The 119 study recruited 1.802 participants aged  $\geq$  18 years with a diagnosis of diabetes made 120 within the previous 12 months. Participants with gestational and secondary diabetes 121 were excluded from the study. The StartRight study was enriched for late-onset type 122 1 diabetes by aiming for equal recruitment of those receiving and not receiving insulin 123 therapy in those with diabetes onset after 50 years. For our analysis, we considered 124

only individuals of White ancestry with a clinical diagnosis of type 2 diabetes and
 confirmed negative islet autoantibody status.

#### 127 Assessment of the phenotypic characteristics of interest

Regarding the UDIP study, information on the demographic (age, sex, and residence) and clinical (family history of diabetes and history of co-existing hypertension) characteristics of interest was collected from each study participant. This was followed by resting blood pressure and anthropometric measurement and the systolic and diastolic blood pressure, weight, height, waist circumference (WC), hip circumference (HC), BMI, and waist: hip circumference ratio (WHR) were recorded.

A fasting venous blood sample was then drawn for the measurement of glycated 134 hemoglobin (HbA1c), lipid profile, C-peptide, and three islet autoantibodies (glutamic 135 acid decarboxylase-65 or GADA, tyrosine phosphatase or IA-2A, and zinc transporter 136 8 or ZnT8-A). All participants were subjected to a 75-gram oral glucose tolerance test 137 138 (OGTT) to measure the 120-minute C-peptide concentrations. All the above tests were carried out at the Medical Research Council/Uganda Virus Research Institute and 139 London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe 140 141 Uganda.

For the StartRight study, demographic and clinical information was collected at the recruitment visit with an assessment of height, weight, waist, and hip circumference measurements to calculate the BMI and WHR. This was followed by the collection of a nonfasted (within 1-5 hours post-meal) blood sample for DNA extraction, and measurement of C-peptide, glucose, HbA1c, and islet autoantibodies (GADA, IA-2A, and ZnT8A) concentrations. These tests were performed at the academic Blood Sciences Department at the Royal Devon and Exeter Hospital, Exeter UK.

149 Assessment of type 1 and type 2 diabetes Genetic Risk Score

In addition to screening for the three islet autoantibodies, we calculated type 1 diabetes (T1D) and T2D genetic risk scores (GRS). The T1D GRS was calculated based on the 67 Single Nucleotide Polymorphisms (SNPs) reported to be associated with T1D, as described by Sharp et al [16]. The T2D GRS was calculated using T2Dassociated SNPs from a European population [17] which was shown to effectively predict T2D across racial/ethnic groups [18].

#### 156 **Definition of the study outcomes**

Early-onset and late-onset T2D were defined as T2D diagnosed at <40 years and ≥40 years, respectively, with confirmed islet autoantibody negative status in both populations. Ugandan participants were considered to be islet autoantibody negative if the GADA, IA-2A, and ZnT8-A concentrations were ≤34 U/ml, ≤58 U/ml, and ≤67.7 U/ml, respectively, based on the 97.5<sup>th</sup> centile of 600 adult rural Ugandans without diabetes.

Islet autoantibody negative status was considered in the White European participants if the GADA and IA-2A concentrations were <11 U/ml and <7.5 U/ml, respectively. Cutoffs of <65 U/ml and <10 U/ml were used for the ZnT8-A concentration in participants aged <30 years and  $\geq$ 30 years, respectively [19]. These cut-offs represented the  $\geq$ 97.5<sup>th</sup> percentile of 1,559 British participants without diabetes.

168 Obesity was defined based on the traditional World Health Organisation cut-off of  $\geq$  30 169 kg/m<sup>2</sup>.

#### 170 Statistical analysis

Percentages and medians with their corresponding interquartile range (IQR) were used to describe the categorical and continuous variables, respectively. The demographic, clinical, anthropometric, and metabolic characteristics of the participants with early-onset and late-onset T2D were analyzed using Fisher's exact

test for categorical data and the two-sample t-tests for continuous data. The
categorical and continuous variables were expressed as proportions and mean with
95% confidence intervals (CI), respectively. All analyses were performed using STATA
statistical software version 15 (StataCorp, USA).

#### 179 Ethical approval

This UDIP study was approved by the Research Ethics Committee of Uganda Virus Research Centre, Entebbe Uganda (GC/127/18/05/650) and the Uganda National Council of Science and Technology (HS 2431), with administrative approval from all participating study sites. The StartRight study was approved by the South West– Cornwall and Plymouth NHS Research Ethics Committee (16/SW/0130). All enrolled study participants provided written informed consent to participate in the study.

#### 186 **RESULTS**

# 187 Characteristics of the White European and Ugandan participants with islet 188 autoantibody negative type 2 diabetes

The overall characteristics of the White European and Ugandan participants with isletautoantibody negative type 2 diabetes are summarized in Table 1.

Compared with the White European participants, adult Ugandans with islet 191 autoantibody negative type 2 diabetes were younger (mean [95% CI]- 48.4 [47.2-49.5] 192 years vs. 51.2 [50.2-52.2] years) with lower markers of adiposity (mean [95% CI] BMI 193 of 27.7 [27.2-28.2] kg/m<sup>2</sup> vs. 33.6 [33.0-34.2] kg/m<sup>2</sup>, and BMI  $\geq$ 30 kg/m<sup>2</sup> - 34.2% vs. 194 66.4%). Additionally, Ugandan participants had a higher HbA1c (mean [95% CI] 195 HbA1c - 88.2 [85.0-91.3] mmol/mol vs. 73.2 [71.2-75.2] mmol/mol), and lower 196 pancreatic beta-cell function (mean [95% CI] post-meal or 120-minute post-glucose 197 load C-peptide- 1197.79 [1096.34-1299.25] pmol/L vs. 2054.16 [1975.73-2132.58] 198 pmol/L) at the time of recruitment. 199

#### In White Europeans, early onset T2D is strongly associated with a female

#### 201 predominance and markers of obesity

- The characteristics of the adult White European and Ugandan participants with earlyonset and late-onset T2D are shown in Table 2 and Figure 1.
- Of the 500 Ugandan and 714 White European participants enrolled in the UDIP and
- UK StartRight studies with autoantibody negative T2D, 134 (26.8%) and 113 (15.8%)
- had early-onset T2D, respectively.
- 207 Compared with late-onset T2D, early-onset T2D in the White European participants
- was significantly associated with a female predominance (52.2% vs. 39.1%, p=0.01),
- increased BMI (mean [95% CI]- 36.7 [35.2-38.1] kg/m<sup>2</sup> vs. 33.0 [32.4-33.6] kg/m<sup>2</sup>,
- 210 p<0.001), WC (112.4 [109.1-115.6] cm vs. 108.8 [107.6-110.1] cm, p=0.06), and a
- 211 higher frequency of obesity (82.3% vs. 63.4%, p<0.001).
- Conversely, compared with those with late-onset T2D, Ugandan participants with
  early-onset T2D had lower markers of adiposity (mean [95% CI] WC- 93.1 [89.9-96.3]
  cm vs. 97.4 [95.9-98.8], p=0.006). No differences were noted in the proportion of
  females (53.0% vs. 57.9%, p=0.32), frequency of obesity (32.6% vs. 35.2%, p=0.48),
  and BMI levels (mean [95% CI]- 27.3 [26.2-28.4] kg/m<sup>2</sup> vs. 27.9 [27.3-28.5] kg/m<sup>2</sup>) in
  Ugandan participants with early-onset and late-onset T2D.

Early onset T2D in Ugandans is associated with marked hyperglycemia and pancreatic beta cell failure

Ugandan participants with early-onset T2D had a greater degree of hyperglycemia
(mean [95% CI] HbA1c- 96.3 [89.7-102.9] mmol/mol vs 85.3 [81.7-88.8] mmol/mol,
p=0.004) and pancreatic beta-cell dysfunction (mean [95% CI] 120-minute postglucose load C-peptide level- 896.08 [780.91-1011.24] pmol/L vs 1310.10 [1179.241440.95] pmol/L, p<0.001) at the time of recruitment. In contrast, the post-meal C-</li>

peptide levels did not differ in the White European participants with early-onset and
late-onset T2D (mean [95% CI]- 2130.94 [1905.12-2356.76] pmol/L vs. 2039.72
[1956.52-2122.92] pmol/L, p=0.62).

228 Genetic risk score of the adult Ugandan and White European participants with

### 229 early-onset type 2 diabetes

Ugandan participants with early-onset T2D had a higher T2D GRS when compared
with those with late-onset T2D (11.28 [11.21-11.34] vs. 11.22 [11.18-11.25], p=0.09).
Similarly, compared with those with late-onset T2D, White European participants with
early-onset T2D also had a higher T2D GRS (11.25 [11.19-11.31] vs. 11.20 [11.1711.22], p=0.08), although the differences in both cohorts were not statistically
significant.

#### 236 **DISCUSSION**

To our knowledge, this is the first study to rigorously investigate the manifestation of early-onset and late-onset T2D in an adult Black African population and to make comparisons with a White European population. We demonstrate striking differences in presentation between these two populations, where, in contrast to the White European cohort, early-onset T2D in adult Ugandans is likely to be seen more in patients without obesity (and other features of the metabolic syndrome), and is associated with marked pancreatic beta-cell dysfunction.

The association between obesity and early-onset T2D in White European populations has been well documented and suggests a common underlying mechanism, driven by insulin resistance as a primary defect and pancreatic beta-cell dysfunction occurring later [4, 20-22]. However, beta-cell failure appears to occur more rapidly in patients with early-onset T2D compared with those with late-onset T2D [9, 11]. In addition,

early-onset T2D in White European participants was common among females, which
has also been widely reported in other studies of White populations [23, 24].

251 In contrast, the pathways that lead to the early onset of T2D in Africa, where it occurs in the absence of excessive adiposity, are unclear, but most evidence suggests that 252 pancreatic beta-cell dysfunction is the primary defect. This may result from genetic 253 predisposition as well as environmental exposures, such as early-life (in-utero and/or 254 255 early childhood) malnutrition and infections like tuberculosis, HIV, and malaria, which are prevalent in the region [25-28]. This notion forms the basis of the developmental 256 257 origins of health and disease (DOHaD), which explains that such early-life environmental exposures may induce changes, including epigenetic, that alter gene 258 expression, cellular growth, composition, and physiology, increasing the future risk of 259 developing cardiometabolic conditions like T2D [29]. The high burden of infectious 260 diseases, such as tuberculosis and HIV, may also act directly or indirectly in adulthood 261 to increase the risk of developing early-onset T2D [25, 26]. 262

The unique manifestation of early-onset T2D with a predominance of pancreatic beta-263 cell dysfunction, as seen in adult Ugandans, may also be due to genetic influences. 264 265 Polymorphisms of genes that influence pancreatic beta-cell development, proliferation, neogenesis, apoptosis, and insulin secretion such as the transcription 266 factor-7 like 2 genes (TCF7L2), Zinc Finger RANBP2-Type Containing 3 (ZRANB3), 267 and the ATP-sensitive potassium channel Kir6.2 gene (KCNJ11), have been 268 suggested as possible mechanisms for pancreatic beta-cell dysfunction in patients of 269 African ancestry [30-32]. 270

271 Strengths of the study include that this is the first study to undertake phenotypic 272 characterization of early-onset and late-onset T2D (where islet-cell autoimmunity has 273 been robustly screened for and excluded) in adult Black African and White European

patients with recently diagnosed diabetes, to investigate if ethnic-related differences 274 exist in the manifestation of early-onset T2D. Participants were phenotyped in detail, 275 and GRS was available to investigate the potential contribution of antibody-negative 276 T1D and classical T2D genetic susceptibility to early-onset antibody-negative T2D. 277 Limitations of this study include differences in the designs of the two studies which 278 may limit the interpretation of some findings. For example, the differences in the study 279 280 design (including age-related recruitment in the StartRight study) suggest that these studies should not be used to directly compare the relative prevalence of early-onset 281 282 T2D. In addition, the post-meal C-peptide measurement in the StartRight study may not be directly comparable to the 120-minute post-glucose load C-peptide 283 measurement used in the UDIP study, and differences in duration at recruitment may 284 impact direct comparison of glycemic control. Ugandan participants were recruited 285 only from seven secondary hospitals (in contrast to the combined primary and 286 287 secondary healthcare recruitment in the StartRight study).

In conclusion, our study findings demonstrate that the phenotypic profile of early-onset 288 T2D in adult Ugandans and White Europeans with recently diagnosed diabetes greatly 289 differs. While obesity plays a central role in the pathogenesis of early-onset T2D in 290 White Europeans, its effect in adult Ugandans is insignificant. Pancreatic beta-cell 291 dysfunction appears to explain the early onset of T2D in this population. An in-depth 292 understanding of the phenotype of early-onset T2D in Black African and White 293 European populations is important and has significant clinical and therapeutic 294 implications. Because of these phenotypic differences, the therapeutic and preventive 295 strategies for early-onset T2D should be tailored to ethnicity and population. Due to a 296 lack of adequate clinical evidence, future research is needed to guide how to optimally 297 manage and prevent early-onset T2D, especially in adult Ugandans. 298

#### 299 Acknowledgments

The authors are grateful to all the study participants who consented to join the study, 300 the UDIP and StartRight research teams, the staff of the Clinical Diagnostics 301 Laboratory Services at the Medical Research Council/Uganda Virus Research 302 Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, 303 Entebbe, Uganda, and the academic Blood Sciences Department, Royal Devon and 304 305 Exeter Hospital, UK, for conducting the laboratory tests. The authors also thank the ADDRESS-2 study team (Imperial College, London, UK) for support with participant 306 307 recruitment in the StartRight study.

### 308 Data availability statement

The datasets generated during and/or analyzed in the current study are available fromthe corresponding author upon reasonable request.

#### 311 Funding and Assistance

This UDIP study was supported by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (Project Reference: MC\_UP\_1204/16), and the National Institute for Health Care Research (NIHR) (17/63/131). The StartRight study was funded by the National Institute for Health and Care Research (NIHR) (CS-2015-15-018) and Diabetes UK (17/0005624). Genetic analysis for the StartRight study was funded by the European Foundation for the Study of Diabetes (2016 Rising Star Fellowship).

JCK is supported by the NIHR Exeter Biomedical Research Centre (NIHR Exeter BRC). ATH is supported by the NIHR Exeter Clinical Research Facility and an NIHR Senior Investigator award. AGJ was supported for this work by an NIHR Clinician Scientist award (CS-2015-15-018). MJN is an MRC Investigator.

- 323 The study sponsor/funder was not involved in the design of the study; the collection,
- analysis, and interpretation of data; writing the report; and did not impose any
- restrictions regarding the publication of the report.

#### 326 Authors' relationships and activities

327 No potential conflicts relevant to this article were reported.

#### 328 **Contribution statement**

DK and JCK wrote the first draft of the manuscript, DK and AVH participated in the 329 study design, data acquisition, analysis, and interpretation, JCK, IS and JK 330 participated in the study design, data analysis, and interpretation, and reviewed all the 331 versions of the manuscript, WL participated in the data collection process, and data 332 interpretation, SS performed the genetic analysis and reviewed all the versions of the 333 manuscript, AGJ, ATH, LS, and MJN supervised this work, received funding for the 334 entire research project, reviewed, and edited all versions of the manuscript. All authors 335 read and approved the final draft of the manuscript. DK is the guarantor of this work 336 and, as such, had full access to all the data in the study and takes responsibility for 337 the integrity of the data and the accuracy of the data analysis. 338

#### 339 **REFERENCES**

- Xie J, Wang M, Long Z, et al (2022) Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019. BMJ 379:e072385.
- Perng W, Conway R, Mayer-Davis E, Dabelea D (2023) Youth-Onset Type 2
   Diabetes: The Epidemiology of an Awakening Epidemic. Diabetes Care
   46(3):490-499.

- Chowdhury TA, Lasker SS (2002) Complications and cardiovascular risk
   factors in South Asians and Europeans with early-onset type 2 diabetes. QJM
   95(4):241-246.
- Misra S, Holman N, Barron E, et al (2023) Characteristics and care of young
  people with type 2 diabetes included in the national diabetes audit datasets for
  England. Diabet Med 40(1):e14940.
- 352 5. Prasad RB, Asplund O, Shukla SR, et al (2022) Subgroups of patients with
  353 young-onset type 2 diabetes in India reveal insulin deficiency as a major driver.
  354 Diabetologia 65(1):65-78.
- Siddiqui MK, Anjana RM, Dawed AY, et al (2022) Young-onset diabetes in
  Asian Indians is associated with lower measured and genetically determined
  beta cell function. Diabetologia 65(6):973-983.
- 358 7. Barker MM, Zaccardi F, Brady EM, et al (2022) Age at diagnosis of type 2
  359 diabetes and cardiovascular risk factor profile: A pooled analysis. World J
  360 Diabetes 13(3):260-271.
- Song SH, Hardisty CA (2009) Early onset type 2 diabetes mellitus: a harbinger
   for complications in later years—clinical observation from a secondary care
   cohort. QJM 102(11):799-806.
- Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S (2018) Type 2
   diabetes in adolescents and young adults. Lancet Diabetes Endocrinol 6(1):69 80.
- Magliano DJ, Sacre JW, Harding JL, Gregg EW, Zimmet PZ, Shaw JE (2020)
   Young-onset type 2 diabetes mellitus implications for morbidity and mortality.
   Nat Rev Endocrinol 16(6):321-331.

- Misra S, Ke C, Srinivasan S, Goyal A, et al (2023) Current insights and
  emerging trends in early-onset type 2 diabetes. Lancet Diabetes Endocrinol
  11(10):768-782.
- Wilmot E, Idris I (2014) Early onset type 2 diabetes: risk factors, clinical impact
  and management. Ther Adv Chronic Dis 5(6):234-244.
- Wilmot EG, Davies MJ, Yates T, Benhalima K, Lawrence IG, Khunti K (2010)
  Type 2 diabetes in younger adults: the emerging UK epidemic. Postgrad Med
  J 86(1022):711-718.
- Kiraka GN, Kunyiha N, Erasmus R, Ojwang PJ (2014) Family history as a risk
  for early-onset type 2 diabetes in Kenyan patients. African Journal of Diabetes
  Medicine 22(2):15-17.
- Adadey SM, Mensah JA, Acquah KS, Abugri J, Osei-Yeboah R (2023) Earlyonset diabetes in Africa: A mini-review of the current genetic profile. Eur J Med
  Genet 66(12):104887.
- Sharp SA, Rich SS, Wood AR, et al (2019) Development and Standardization
  of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn
  Screening and Incident Diagnosis. Diabetes Care 42(2):200-207.
- Mahajan A, Taliun D, Thurner M, et al (2018) Fine-mapping type 2 diabetes loci
  to single-variant resolution using high-density imputation and islet-specific
  epigenome maps. Nat Genet 50(11):1505-1513.
- 390 18. Oram RA, Sharp SA, Pihoker C, et al (2022) Utility of Diabetes Type-Specific
  391 Genetic Risk Scores for the Classification of Diabetes Type Among Multiethnic
  392 Youth. Diabetes Care 45(5):1124-1131.

393 19. Grace SL, Cooper A, Jones AG, McDonald TJ (2021) Zinc transporter 8
autoantibody testing requires age-related cut-offs. BMJ Open Diabetes Res
Care 9(1):e002296.

- Benhalima K, Song SH, Wilmot EG, et al (2011) Characteristics, complications
  and management of a large multiethnic cohort of younger adults with type 2
  diabetes. Prim Care Diabetes 5(4):245-250.
- Hillier TA, Pedula KL (2001) Characteristics of an adult population with newly
  diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes
  Care 24(9):1522-1527.
- 402 22. Hou C, Yang H, Qu Y, et al (2022) Health consequences of early-onset
  403 compared with late-onset type 2 diabetes mellitus. Precis Clin Med
  404 5(2):pbac015.
- Frayling TM, Wiltshire S, Hitman GA, et al (2003) Young-onset type 2 diabetes
  families are the major contributors to genetic loci in the Diabetes UK Warren 2
  genome scan and identify putative novel loci on chromosomes 8q21, 21q22,
  and 22q11. Diabetes 52(7):1857-1863.
- Zhou K, Donnelly LA, Morris AD, et al (2014) Clinical and genetic determinants
  of progression of type 2 diabetes: a DIRECT study. Diabetes Care 37(3):718724.
- 412 25. Goedecke JH, Mendham AE (2022) Pathophysiology of type 2 diabetes in sub413 Saharan Africans. Diabetologia 65(12):1967-1980.
- Kibirige D, Lumu W, Jones AG, Smeeth L, Hattersley AT, Nyirenda MJ (2019)
  Understanding the manifestation of diabetes in sub Saharan Africa to inform
  therapeutic approaches and preventive strategies: a narrative review. Clin
  Diabetes Endocrinol 5:2.

- Christensen DL, Hjort L, Mpagama SG, Ramaiya KL (2023) Environmental
  exposures are important for type 2 diabetes pathophysiology in sub-Saharan
  African populations. Diabetologia 66(4):777-779.
- 421 28. Ferdous F, Filteau S, Schwartz NB, Gumede-Moyo S, Cox SE (2022)
  422 Association of postnatal severe acute malnutrition with pancreatic exocrine and
  423 endocrine function in children and adults: a systematic review. Br J Nutr
  424 129(4):1-34.
- 425 29. Hoffman DJ, Reynolds RM, Hardy DB (2017) Developmental origins of health
  426 and disease: current knowledge and potential mechanisms. Nutrition Reviews
  427 75(12):951-970.
- 30. Adeyemo AA, Tekola-Ayele F, Doumatey AP, et al (2015) Evaluation of
  Genome Wide Association Study Associated Type 2 Diabetes Susceptibility
  Loci in Sub Saharan Africans. Front Genet 6:335.
- 431 31. Adeyemo AA, Zaghloul NA, Chen G, et al (2019) ZRANB3 is an African-specific
  432 type 2 diabetes locus associated with beta-cell mass and insulin response. Nat
- 433 Commun 10(1):3195.
- 434 32. Chen J, Sun M, Adeyemo A, et al (2019) Genome-wide association study of
  435 type 2 diabetes in Africa. Diabetologia 62(7):1204-1211.
- 436
- 437
- 438
- 439

#### Table 1. Overall characteristics of the adult White Europeans and Black 441

#### Ugandans with recently diagnosed type 2 diabetes 442

Characteristics	Adult White European participants with recently diagnosed T2D (n= 714)	Adult Black Ugandan participants with recently diagnosed T2D (n= 500)
Age at diagnosis (years)	51.2 (50.2-52.2)	48.4 (47.2-49.5)
Female, n (%)	294 (41.2%)	283 (56.6%)
Parental history of T2D, n (%)	318 (44.5%)	191 (38.2%)
Co-existing hypertension, n (%)	268 (37.5%)	171 (35.0%)
Systolic blood pressure, mmHg	134.4 (133.1-135.7)	126.8 (125.2-128.0)
Diastolic blood pressure, mmHg	81.0 (80.2-81.8)	84.1 (83.1-85.0)
Body mass index, kg/m <sup>2</sup>	33.6 (33.0-34.2)	27.7 (27.2-28.2)
Body mass index ≥30 kg/m², n (%)	474 (66.4%)	171 (34.2%)
Waist circumference, cm	109.4 (108.2-110.6)	96.3 (94.9-97.6)
Hip circumference, cm	113.6 (112.5-114.6)	104.2 (102.3-106.1)
Waist: hip ratio	0.96 (0.96-0.97)	0.92 (0.91-0.93)
TC, mmol/l	5.20 (5.05-5.35)	4.17 (4.05-4.29)
HDLC, mmol/l	1.18 (1.13-1.24)	0.95 (0.74-1.20)
LDLC, mmol/l	2.95(2.83-3.06)	2.71 (2.61-2.81)
TGL, mmol/l	3.40 (2.88-3.93)	1.59 (1.50-1.67)
HbA1c, mmol/mol	73.2 (71.2-75.2)	88.2 (85.0-91.3)
HbA1c, %	8.8 (8.7-9)	10.2 (9.9-10.5)
Random/120-minute post-OGTT	2054.16 (1975.73-2132.58)	1197.79 (1096.34-1299.25)
C-peptide, pmol/L*		

Continuous data is expressed as mean (95% CI), \*Random or nonfasted, and 120-443

minute post-OGTT load C-peptide concentrations used for the White European and 444

Ugandan participants, respectively. 445

	Adult White European population with recently diagnosed type 2 diabetes (n= 714)		Adult Black Ugandan population with recently diagnosed type 2 diabetes (n= 500)			
Characteristics	<40 years	≥40 years	P-value	<40 years	≥40 years	P-value
	(n= 113, 15.8%)	(n= 601, 84.2%)		(n= 134, 26.8%)	(n= 366, 73.2%)	
Age at diagnosis (years)	32.7 (31.7-33.7)	54.7 (53.8-55.5)		32.9 (32.0-33.8)	54.0 (53.0-55.0)	
Female, n (%)	59 (52.2%)	235 (39.1%)	0.01	71 (53.0%)	212 (57.9%)	0.32
Parental history of T2D, n (%)	56 (49.6%)	262 (43.6%)	0.26	54 (40.3%)	137 (37.4%)	0.68
Co-existing HT, n (%)	12 (10.6%)	256 (42.6%)	<0.001	16 (11.9%)	155 (42.4%)	<0.001
Systolic BP, mmHg	127.8 (125.3-130.3)	135.6 (134.2-137.0)	<0.001	120 (117-122)	129 (127-131)	<0.001
Diastolic BP, mmHg	80.2 (78.4-82.0)	81.1 (80.3-82.0)	0.27	81 (79-83)	85 (84-86)	<0.001
BMI, kg/m²	36.7 (35.2-38.1)	33.0 (32.4-33.6)	<0.001	27.3 (26.2-28.4)	27.9 (27.3-28.5)	0.29
BMI ≥30 kg/m², n (%)	93 (82.3%)	381 (63.4%)	<0.001	43 (32.6%)	128 (35.2%)	0.48
Waist circumference, cm	112.4 (109.1-115.6)	108.8 (107.6-110.1)	0.06	93.1 (89.9-96.3)	97.4 (95.9-98.8)	0.006
Hip circumference, cm	119.4 (116.5-122.3)	112.5 (111.4-113.6)	<0.001	104.2 (98.4-110.0)	104.2 (102.7-105.7)	0.99
Waist: hip ratio	0.94 (0.93-0.96)	0.97 (0.96-0.98)	0.003	0.89 (0.88-0.91)	0.93 (0.92-0.94)	<0.001
Total cholesterol, mmol/l	5.65 (4.97-6.32)	5.12 (5.00-5.25)	0.17	4.03 (3.83-4.20)	4.22 (4.08-4.36)	0.17
HDLC, mmol/l	1.04 (0.96-1.13)	1.21 (1.15-1.27)	0.002	0.94 (0.70-1.15)	0.96 (0.76-1.23)	0.52
LDLC, mmol/l	3.11 (2.84-3.39)	2.92 (2.80-3.05)	0.22	2.56 (2.38-2.73)	2.76 (2.64-2.88)	0.07
Triglycerides, mmol/l	3.87 (1.68-6.06)	3.33 (2.83-3.83)	0.29	1.54 (1.39-1.70)	1.60 (1.50-1.71)	0.55
HbA1c, mmol/mol	77.6 (72.5-82.8)	72.4 (70.2-74.5)	0.049	96.3 (89.7-102.9)	85.3 (81.7-88.8)	0.004
HbA1c, %	9.3 (8.8-9.7)	8.8 (8.6-9.0)	0.049	10.9 (10.3-11.5)	9.9 (9.6-10.3)	0.004
Random/120-minute post-	2130.94 (1905.12-	2039.72 (1956.52-	0.62	896.08 (780.91-	1310.10 (1179.24-	<0.001
OGTT C-peptide, pmol/L*	2356.76)	2122.92)		1011.24)	1440.95)	
T1D GRS	10.42 (9.93-10.92)	10.07 (9.88-10.26)	0.14	8.43 (8.03 - 8.81)	8.12 (7.89 - 8.36)	0.20
T2D GRS	11.25 (11.19-11.31)	11.20 (11.17-11.22)	0.08	11.28 (11.21-11.34)	11.22 (11.18-11.25)	0.09

## Table 2. Characteristics of adult White European and Ugandan participants with early-onset and late-onset type 2 diabetes

Continuous data is expressed as mean (95% CI), \*Random or nonfasted and 120-minute post-OGTT load C-peptide concentrations used for the White European and Ugandan participants, respectively.

Figure 1. Comparison of the female sex distribution, body mass index, waist circumference, and post-glucose or meal C-peptide levels between the White European and Ugandan participants with early-onset and late-onset type 2 diabetes



**BMI-** Body mass index